Borchmann P - Search Results

1

State of the art in the treatment of Hodgkin lymphoma.

Borchmann P, Eichenauer DA, Engert A. Borchmann P, et al. Nat Rev Clin Oncol. 2012 Jun 12;9(8):450-9. doi: 10.1038/nrclinonc.2012.91. Nat Rev Clin Oncol. 2012. PMID: 22688578 Review.

2

[Chronic lymphatic leukemia. Progress in diagnosis and therapy].

Borchmann P, Diehl V, Engert A. Borchmann P, et al. Internist (Berl). 1996 Oct;37(10):1022-9. Internist (Berl). 1996. PMID: 9019446 Review. German. No abstract available.

3

Idarubicin: a brief overview on pharmacology and clinical use.

Borchmann P, Hübel K, Schnell R, Engert A. Borchmann P, et al. Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Int J Clin Pharmacol Ther. 1997. PMID: 9147715 Review.

4

A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.

Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. Hübel K, et al. Among authors: borchmann p. Leukemia. 1997 Dec;11 Suppl 5:S47-51. Leukemia. 1997. PMID: 9436939 Clinical Trial.

5

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Schnell R, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Aug;30(5-6):525-37. doi: 10.3109/10428199809057565. Leuk Lymphoma. 1998. PMID: 9711915 Clinical Trial.

6

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. Reiser M, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Oct;31(3-4):359-66. doi: 10.3109/10428199809059229. Leuk Lymphoma. 1998. PMID: 9869200 Clinical Trial.

7

New drugs in the treatment of Hodgkin's disease.

Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.

8

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.

Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Leukemia. 2000 Jan;14(1):129-35. doi: 10.1038/sj.leu.2401626. Leukemia. 2000. PMID: 10637488 Clinical Trial.

9

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, Hübel K, Staib P, Schulz A, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 2001 May;12(5):661-7. doi: 10.1023/a:1011139016294. Ann Oncol. 2001. PMID: 11432625 Free article. Clinical Trial.

10

[Monoclonal antibodies: development and clinical prospects].

Borchmann P, Riethmüller G, Engert A. Borchmann P, et al. Internist (Berl). 2001 Jun;42(6):803-4, 807-14. doi: 10.1007/s001080170123. Internist (Berl). 2001. PMID: 11449627 Review. German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters